FDA clarifies wearable rules

A smartwatch can count your steps, estimate your sleep, and graph your heart rate for months without much trouble. The legal problem starts when the same watch sounds less like a coach and more like a clinic. (fda.gov) On January 6, 2026, the Food and Drug Administration reissued its final guidance on “General Wellness: Policy for Low Risk Devices,” and the agency said it was giving industry and agency staff more clarity on products that promote a healthy lifestyle. The update matters for wearables because many bands, rings, and watches now estimate physiological measures like sleep and recovery. (fda.gov 1) (fda.gov 2) The Food and Drug Administration draws the line with “intended use,” which is the product’s stated job in its labels, ads, and app screens. If a company says a wearable helps users maintain or encourage a healthy lifestyle, the agency can treat it as general wellness instead of a medical device it actively reviews. (fda.gov) (natlawreview.com) The guidance keeps two gates in place. A product must make only a general wellness claim, and it must present a low risk to users. (fda.gov) A general wellness claim usually points to everyday habits like exercise, weight management, sleep management, relaxation, mental acuity, or stress reduction. The Food and Drug Administration also allows some claims tying those habits to lower risk of chronic disease, as long as the link is already well understood, like physical activity helping reduce the risk of high blood pressure. (fda.gov) Low risk has a plain meaning here. The product cannot be invasive, cannot be implanted, cannot involve an intervention or technology that poses a safety risk to users, and cannot raise novel questions of usability. (fda.gov) That is why wording now does so much work. A ring that says it shows “sleep trends” or “recovery insights” is trying to stay in the lifestyle lane, while a ring that says it detects insomnia or diagnoses overtraining is stepping toward medical-device territory. (natlawreview.com) (fda.gov) The 2026 discussion around wearables focuses on products that estimate physiological measures rather than directly diagnose disease. The National Law Review article says the updated policy clarifies how the Food and Drug Administration applies the old framework to newer wearable features, especially when companies present activity, sleep, and recovery data to consumers. (natlawreview.com) If a company crosses the line, the consequences are expensive and slow. Medical devices can trigger requirements tied to premarket review, registration and listing, labeling, quality system rules, and medical device reporting that general wellness products usually avoid under this policy. (fda.gov) (natlawreview.com) So the fight is no longer just over sensors and battery life. It is over whether a dashboard, push alert, or marketing sentence makes a wearable look like a fitness journal or a diagnostic tool. (natlawreview.com)